Search research articles
Contact Us
Filters
Showing results (81-90 of 103) with videos related to
Page
of 11
Sort By:
The Journal of Infectious Diseases
|
September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Annals of Internal Medicine
|
February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 27, 2023
Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings
Marta Epeldegui, Di Chang, Jeannette Lee, et al.
The New England Journal of Medicine
|
December 3, 2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
The Journal of Clinical Investigation
|
July 16, 2019
Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance
Serena Spudich, Kevin R Robertson, Ronald J Bosch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
N Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
The Lancet. HIV
|
October 2, 2015
Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial
Robert Gross, Lu Zheng, Alberto La Rosa, et al.
Lancet (London, England)
|
March 9, 2020
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
Susan E Krown, Carlee B Moser, Patrick MacPhail, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257
Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 103) with videos related to
Sort By:
Page
of 11
The Journal of Infectious Diseases
|
September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Annals of Internal Medicine
|
February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1
Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 27, 2023
Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings
Marta Epeldegui, Di Chang, Jeannette Lee, et al.
The New England Journal of Medicine
|
December 3, 2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
Paul E Sax, Camlin Tierney, Ann C Collier, et al.
The Journal of Clinical Investigation
|
July 16, 2019
Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance
Serena Spudich, Kevin R Robertson, Ronald J Bosch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
N Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
The Lancet. HIV
|
October 2, 2015
Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial
Robert Gross, Lu Zheng, Alberto La Rosa, et al.
Lancet (London, England)
|
March 9, 2020
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
Susan E Krown, Carlee B Moser, Patrick MacPhail, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257
Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
Page
of 11